Cure My Disease

Don't miss your cure!

 Log in / Sign up

A quick pill and an EEG may spot schizophrenia in hours, not years

NCT ID NCT03781115

Diagnosis Sponsor: University of Arizona Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study explores whether people with schizophrenia resist the sedating effects of antipsychotic drugs like ziprasidone and olanzapine. Researchers give a single dose to both patients and healthy volunteers, then measure sleepiness, reflexes, and brain activity using EEG. If patients stay more alert than healthy people, those differences could form the basis of a rapid, low-cost diagnostic test for schizophrenia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ziprasidone (Geodon) and Olanzapine (Zyprexa) — antipsychotic drugs used as a single-dose diagnostic probe
What this could lead to
If it works, this could lead to a simple, inexpensive diagnostic test for schizophrenia, reducing the months or years it often takes to get a clear diagnosis.
What could go wrong
This is a small early-phase study with only 24 participants, so results may not apply broadly. The test relies on subjective sleepiness scales and EEG changes, which may not be reliable enough for a definitive diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2017

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Healthy Control 1. Be between 18 and 40 years of age 2. Be able to understand English 3. Have no history of psychosis 4. Have no history of sleep apnea, heart condition or seizure 5. Have no known drug allergies 6. The ability to swallow a pill Exclusion Criteria Healthy control 1. Refuse to sign the consent form 2. Drink caffeine or alcohol within 24 hours of the study 3. Have the EKG readout report borderline or abnormal ECG 4. Have the 12 panel urine drug screen show a positive result 5. Be pregnant Inclusion Criteria Schizophrenic subject 1. Be between 18 and 40 years of age 2. Be able to understand English 3. Have been diagnosed with a Schizophrenia Spectrum or other psychotic disorder 4. Belong to one of three groups: 1. Never medicated patients with a first episode of psychosis 2. Have not received long acting injectable (depot) antipsychotic in previous 6 months 3. Have not received oral antipsychotic (or antidepressant that has serotonergic action) in previous 2 weeks 5. Have no history of sleep apnea, heart condition or seizure 6. Have no known drug allergies 7. Be able to swallow a pill 8. Healthy as determined by the enrolling physician(s) Exclusion Criteria Schizophrenic subject 1. Refuse to sign the consent form 2. Drink caffeine or alcohol within 24 hours of the study 3. Have the EKG readout report borderline or abnormal ECG 4. Have the 12 panel urine drug screen show a positive result 5. Be pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophrenia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Psychotic Disorders schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizophrenia

Contacts and locations

Locations

  • Banner University Medical Center

    Phoenix, Arizona, 85006, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.